EUVIMEDEUVIMED entdecken
Crossref

USP33-mediated deubiquitination stabilizes YTHDF2 and promotes glioblastoma malignancy and temozolomide resistance

Shaoshan Shen, Hong Lin, Zongliao Zheng, Lichao Tang, Yihang Ding, Wei Huang, Zhizhou Zhang

Biochemical and Biophysical Research Communications · 2026-10 · 833 · 154387

DOI: 10.1016/j.bbrc.2026.154387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-10. Verfasst von Shaoshan Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, 363000, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Glioblastoma, Temozolomide, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ubiquitin-specific protease 33 (USP33) has been implicated in tumor progression, but its downstream substrates and pharmacological regulation in glioblastoma (GBM) remain poorly defined. Analysis of the TCGA-GBM/LGG cohort revealed a strong positive correlation between USP33 and the N6-methyladenosine reader YTHDF2, and high expression of either gene was associated with unfavorable overall survival. In U87 and U251 cells, USP33 overexpression increased YTHDF2 protein abundance, whereas CRISPR/Cas9-mediated USP33 depletion reduced YTHDF2 protein levels without significantly altering its mRNA expression. Co-immunoprecipitation assays demonstrated an association between USP33 and YTHDF2. Moreover, USP33 loss accelerated YTHDF2 degradation, increased its polyubiquitination, and reduced its abundance through a proteasome-dependent mechanism, supporting YTHDF2 as a previously unrecognized deubiquitination substrate of USP33. Functional rescue experiments showed that YTHDF2 re-expression partially restored proliferation, clonogenic growth, invasion, cell survival, and temozolomide resistance in USP33-deficient GBM cells. To identify pharmacological inhibitors of USP33, we established an Ub-AMC-based enzymatic screening platform and screened a bioactive library containing 4221 compounds. Deoxyshikonin emerged as a prioritized hit and inhibited USP33 deubiquitinase activity with an IC50 of 15.2 μM. In GBM cells, Deoxyshikonin restored YTHDF2 ubiquitination, reduced YTHDF2 protein abundance, and suppressed USP33-driven proliferative phenotypes. Collectively, these findings identify YTHDF2 as a functional substrate of USP33 and suggest that pharmacological inhibition of USP33-mediated YTHDF2 stabilization may represent a potential strategy for limiting GBM malignancy and temozolomide resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsGlioblastomaTemozolomideUbiquitin ThiolesteraseDrug Resistance, NeoplasmBrain NeoplasmsHumansUbiquitinationCell Line, TumorAntineoplastic Agents, AlkylatingCell Proliferation

Stichwörter der Autor:innen

DeoxyshikoninDeubiquitinating enzyme inhibitorGlioblastomaUSP33YTHDF2

Substanzen

RNA-Binding ProteinsTemozolomideUbiquitin ThiolesteraseYTHDF2 protein, humanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, 363000, China.
  • Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, 363000, China. Electronic address: hwfjmu@sina.com.
  • Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, 363000, China. Electronic address: zhangyidao241@sina.com.

Zitieren

APA

Shen, S., Lin, H., Zheng, Z., Tang, L., Ding, Y., Huang, W., & Zhang, Z. (2026). USP33-mediated deubiquitination stabilizes YTHDF2 and promotes glioblastoma malignancy and temozolomide resistance. Biochemical and Biophysical Research Communications, 833, 154387. https://doi.org/10.1016/j.bbrc.2026.154387

Vancouver

Shen S, Lin H, Zheng Z, Tang L, Ding Y, Huang W, et al. USP33-mediated deubiquitination stabilizes YTHDF2 and promotes glioblastoma malignancy and temozolomide resistance. Biochemical and Biophysical Research Communications. 2026;833:154387. doi:10.1016/j.bbrc.2026.154387

BibTeX
@article{Shen2026,
  author = {Shen, Shaoshan and Lin, Hong and Zheng, Zongliao and Tang, Lichao and Ding, Yihang and Huang, Wei and Zhang, Zhizhou},
  title = {USP33-mediated deubiquitination stabilizes YTHDF2 and promotes glioblastoma malignancy and temozolomide resistance},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2026},
  volume = {833},
  pages = {154387},
  doi = {10.1016/j.bbrc.2026.154387}
}
Kostenlos starten →